Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 987,987 1,395,112
Research and Development Expenses 770,430 2,629,741
Stock Based Compensation 69,068 97,000
Warrant Issuance Expenses 762,834
Loss from Operations (2,590,319) (4,121,853)
Other (Income) Expenses    
Interest and Dividend Income (25,824) (120)
(Gain)/Loss on Sales of Marketable Securities (175) 1,650
Change in Fair Value of Marketable Securities 1,712 3,092
Uninsured Casualty Losses (4,442)
Change in Fair Value of Warrant Liabilities (1,175,000)
Change in Fair Value of Derivative Liabilities 120,700
Total Other (Income) Expenses (1,078,587) 180
Loss Before Income Tax (1,511,732) (4,122,033)
Income Tax Benefit
Net Loss (1,511,732) (4,122,033)
Preferred Stock Dividends 158,333
Net Loss Attributable to Common Stockholders $ (1,670,065) $ (4,122,033)
Basic and Dilutive net loss per common share $ (0.04) $ (0.11)
Weighted average basic and diluted common shares outstanding 39,787,242 38,122,928